HeimBVNKF • OTCMKTS
add
Bavarian Nordic
Við síðustu lokun
26,89 $
Dagbil
27,41 $ - 27,41 $
Árabil
18,72 $ - 46,05 $
Markaðsvirði
2,16 ma. USD
Meðalmagn
127,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
CPH
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (DKK) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 1,36 ma. | -0,95% |
Rekstrarkostnaður | 486,03 m. | -22,90% |
Nettótekjur | 70,49 m. | 120,69% |
Hagnaðarhlutfall | 5,17 | 120,89% |
Hagnaður á hvern hlut | 0,90 | -67,86% |
EBITDA | 250,46 m. | -34,15% |
Virkt skatthlutfall | 2,71% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (DKK) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 1,87 ma. | 24,16% |
Heildareignir | 13,95 ma. | 4,10% |
Heildarskuldir | 3,26 ma. | -19,68% |
Eigið fé alls | 10,69 ma. | — |
Útistandandi hlutabréf | 78,32 m. | — |
Eiginfjárgengi | 0,20 | — |
Arðsemi eigna | 1,66% | — |
Ávöxtun eigin fjár | 2,19% | — |
Peningaflæði
Breyting á handbæru fé
| (DKK) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 70,49 m. | 120,69% |
Handbært fé frá rekstri | -71,63 m. | -123,41% |
Reiðufé frá fjárfestingum | 150,15 m. | 249,75% |
Reiðufé frá fjármögnun | 109,92 m. | 1.051,60% |
Breyting á handbæru fé | 180,29 m. | -10,03% |
Frjálst peningaflæði | -914,47 m. | -666,57% |
Um
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany and San Diego, California, as well as offices in Zug, Switzerland, and Morrisville, North Carolina. The company uses viral vectors and virus-like particles in its research and development. Wikipedia
Framkvæmdastjóri
Stofnsett
1. júl. 1992
Vefsvæði
Starfsfólk
1.609
